Jyrki Mattila Net Worth

The estimated Net Worth of Jyrki Mattila is at least $40 mil dollars as of 22 May 2019. Jyrki Mattila owns over 18,750 units of Recro Pharma Inc stock worth over $39,973 and over the last 10 years Jyrki sold REPH stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Jyrki Mattila REPH stock SEC Form 4 insiders trading

Jyrki has made over 1 trades of the Recro Pharma Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently Jyrki exercised 18,750 units of REPH stock worth $721,500 on 22 May 2019.

The largest trade Jyrki's ever made was exercising 18,750 units of Recro Pharma Inc stock on 22 May 2019 worth over $721,500. On average, Jyrki trades about 1,705 units every 0 days since 2015. As of 22 May 2019 Jyrki still owns at least 19,126 units of Recro Pharma Inc stock.

You can see the complete history of Jyrki Mattila stock trades at the bottom of the page.

What's Jyrki Mattila's mailing address?

Jyrki's mailing address filed with the SEC is 675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT, US 84108.

Insiders trading at Recro Pharma Inc

Over the last 11 years, insiders at Recro Pharma Inc have traded over $25,533,136 worth of Recro Pharma Inc stock and bought 3,055,820 units worth $22,429,197 . The most active insiders traders include Healthcare Master Fund Ltd ..., Investment Company, Inc. Awm, eJames E Deerfield Mgmt L.P..... On average, Recro Pharma Inc executives and independent directors trade stock every 31 days with the average trade being worth of $151,953. The most recent stock trade was executed by J David Jr Enloe on 15 March 2022, trading 512 units of REPH stock currently worth $1,004.

What does Recro Pharma Inc do?

Recro Pharma Inc. is a contract development and manufacturing organization (CDMO) with capabilities from early feasibility to commercial manufacturing. With an expertise in solving complex manufacturing problems, Recro is a leading CDMO providing oral solid dosage form development, end-to-end regulatory support, clinical and commercial manufacturing, and packaging and logistics services to the global pharmaceutical market.

Complete history of Jyrki Mattila stock trades at Biospecifics Technologies, Lipocine Inc, eRecro Pharma Inc

Recro Pharma Inc executives and stock owners

Recro Pharma Inc executives and other stock owners filed with the SEC include:

• Geraldine Henwood,
  President, Chief Executive Officer, Director
• Ryan Lake,
  Chief Financial Officer
• William Ashton,
  Independent Director
• Wayne Weisman,
  Independent Chairman of the Board
• Winston Churchill,
  Independent Director
• Michael Berelowitz,
  Independent Director
• Ryan D. Lake,
  Chief Financial Officer
• Bryan Reasons,
  Independent Director
• J. David Enloe Jr.,
  Pres, CEO & Director
• Argot Partners,
  IR Contact Officer
• Tim Bourque,
  VP of Operations & Site Head of San Diego
• David Smithwick B.S.,
  VP of Operations & Site Head of Gainesville
• Richard Sidwell Ph.D.,
  VP & Chief Scientific Officer
• Marshall Rizzo M.B.A.,
  Sr. VP & GM
• Randall J. Mack,
  Sr. VP of Devel.
• Erica Raether M.A.,
  VP of People, Culture & ESG
• William Hirschman,
  VP of Sales & Marketing
• Matthew McKendry,
  Director of Accounting
• Laura L. Parks,
  Director
• Karen Flynn,
  Director
• Vitalife Partners Ii Lp Scp,
  10% owner
• Donna Nichols,
  CAO/Controller
• Stewart Mc Callum,
  Chief Medical Officer
• Randall Mack,
  Senior VP, Development
• Fred Graff,
  Chief Commercial Officer
• Capital Management, Llc Sto...,
  10% owner
• James E Deerfield Mgmt L.P....,
  
• Vitalife Partners (Israel) ...,
  10% owner
• Alfred Altomari,
  Director
• Healthcare Master Fund Ltd ...,
  
• Diane Myers,
  Senior VP-Reg./Quality
• Jyrki Mattila,
  Executive VP, Business Dev.
• Michael Celano,
  Chief Financial Officer
• Arnaud Ajdler,
  Director
• Abraham Ludomirski,
  Director
• Charles Garner,
  CFO and Chief Business Officer
• J David Jr Enloe,
  Chief Executive Officer
• James Charles Miller,
  Director
• Investment Company, Inc. Awm,
  10% owner